Fri, Aug 2, 11:02 AM (88 days ago)
Adaptimmune Therapeutics PLC announced on August 1, 2024, that the U.S. FDA has approved TECELRA® (afamitresgene autoleucel), the first engineered cell therapy for solid tumor cancer in the U.S. This therapy is specifically for adults with unresectable or metastatic synovial sarcoma who have undergone prior chemotherapy and meet certain HLA and MAGE-A4 antigen criteria. This approval marks a significant milestone for Adaptimmune, potentially impacting its financial position and stock value positively. The announcement was made via a press release, which is included as Exhibit 99.1 in the Form 8-K. The company also issued forward-looking statements regarding its future business and financial performance, noting inherent risks and uncertainties.